In Vitro Interleukin‐13 Production by Peripheral Blood in Patients with Newly Diagnosed Insulin‐Dependent Diabetes Mellitus and Their First Degree Relatives
- 1 March 2000
- journal article
- research article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 51 (3) , 321-325
- https://doi.org/10.1046/j.1365-3083.2000.00693.x
Abstract
It is generally accepted that proinflammatory cytokines secreted by macrophages/monocytes as well as cytotoxic T cells are responsible for pancreatic B-cell destruction in animal models of autoimmune diabetes and presumably in insulin-dependent diabetes mellitus (IDDM) in humans. The aim of the present study was to evaluate the production of interleukin (IL)-13–a Th2 cells derived anti-inflammatory cytokine, by peripheral blood of newly diagnosed IDDM patients and their first degree relatives with a low or high risk of IDDM development. The study was carried out in 20 patients with a recent onset of type 1 diabetes, their first degree relatives with high (with DRB1*03 and/or DRB1*04 HLA class II alleles and two or more autoantibodies directed against pancreatic B-cell antigens) (n = 20) or a low (with DQB1*0602 allele) risk of type 1 diabetes development (n = 10) and a control age matched group of healthy volunteers (n = 18). IL-13 concentrations in supernatant of 72 h cultures of peripheral blood after incubation with phytohemagglutinin (PHA) or PHA+ insulin were quantified by enzyme-linked immunosorbent assay (ELISA). The levels of IL-13 in the supernatants were significantly lower in at high risk of IDDM first degree relatives of diabetic patients (P < 0.02), higher in subjects with low genetic risk of diabetes type 1 (P < 0.02), and normal in IDDM patients in comparison to the control group. We have also observed that the adding of human insulin to the cultures resulted in a significant increase of in vitro IL-13 production in prediabetics, but not in the other studied groups. In conclusion our findings suggest that the IL-13 alterations could play an important role in the pathogenesis of type 1 diabetes. We would speculate that IL-13 as an anti-inflammatory cytokine and a mediator of the Th2 pathway could be the potential therapeutic approach in the prevention of type 1 diabetes.Keywords
This publication has 24 references indexed in Scilit:
- Simultaneous Disruption of Interleukin (IL)-4 and IL-13 Defines Individual Roles in T Helper Cell Type 2–mediated ResponsesThe Journal of Experimental Medicine, 1999
- Intergenic Transcription Occurs throughout the Human IL-4/IL-13 Gene ClusterBiochemical and Biophysical Research Communications, 1999
- The distribution of IL-13 receptor α1 expression on B cells, T cells and monocytes and its regulation by IL-13 and IL-4European Journal of Immunology, 1998
- Decreased Secretion of Th2 Cytokines Precedes Up-regulated and Delayed Secretion of Th1 Cytokines in Activated Peripheral Blood Mononuclear Cells from Patients with Insulin-Dependent Diabetes MellitusJournal of Autoimmunity, 1998
- Are there unique autoantigens triggering autoimmune diseases?Immunological Reviews, 1998
- Cytokines and Their Roles in Pancreatic Islet β-Cell Destruction and Insulin-Dependent Diabetes MellitusBiochemical Pharmacology, 1998
- Increased In Vitro Interleukin-12 Production by Peripheral Blood in High-Risk IDDM First Degree RelativesHormone and Metabolic Research, 1997
- Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary cultureEuropean Journal of Immunology, 1996
- Phototyping: comprehensive DNA typing for HLA‐A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence‐specific primers (PCR‐SSP)Tissue Antigens, 1995
- Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cellsImmunology Today, 1994